Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The pharmaceuticals market in Africa is a rapidly growing industry that has been expanding in recent years due to various factors such as population growth, increasing urbanization, and rising healthcare expenditure.
Customer preferences: African consumers are becoming more health-conscious and are demanding better access to healthcare services and products. This has led to an increase in demand for pharmaceuticals, especially for chronic diseases such as diabetes, hypertension, and cancer. Additionally, there is a growing demand for generic drugs due to their affordability and accessibility.
Trends in the market: South Africa has the largest pharmaceuticals market in Africa, followed by Egypt and Nigeria. In South Africa, the market is dominated by multinational companies, while in other countries, local manufacturers play a significant role. There is also a trend towards increasing investment in research and development, which is expected to lead to the development of new and innovative drugs.
Local special circumstances: One of the major challenges facing the pharmaceuticals market in Africa is the lack of infrastructure and healthcare facilities, particularly in rural areas. This has resulted in poor access to healthcare services and medicines, which has led to a rise in counterfeit drugs. Governments in the region are taking steps to address this issue by implementing regulations and increasing investment in healthcare infrastructure.
Underlying macroeconomic factors: The pharmaceuticals market in Africa is expected to continue its growth trajectory due to various macroeconomic factors such as population growth, increasing urbanization, and rising healthcare expenditure. Additionally, the African Continental Free Trade Area (AfCFTA) agreement is expected to boost the pharmaceuticals market by increasing trade and investment in the region. However, the market is also facing challenges such as regulatory barriers, intellectual property rights issues, and limited access to funding.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)